Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Highlights,Welch Group LLC reduced its position in Pfizer,(NYSE:PFE),by over 35% in the fourth quarter.,Institutional ...

Strong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street ...

Pfizer Inc. (NYSE:PFE) reported fourth-quarter adjusted EPS of 63 cents, compared to 10 cents a year ago, beating the ...

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price traded down 0.6% during trading on Tuesday after Citigroup lowered their price target on the stock from $30.00 to $29.00. Citigroup currently has ...

US pharmaceutical giant Pfizer Inc returned to profit in the fourth quarter from a loss in the same period of the previous ...

Pfizer reported $63.6 billion in revenue for the full year, up 7% compared to 2023. The full-year revenue beat Wall Street consensus estimates of $62.9 billion, and earnings per share of $3.12 beat ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...